Business Context and Reporting Period
This Form 6-K filing by Summit Therapeutics plc (a Foreign Private Issuer) covers the month of September 2017. The report details a significant contract award received on September 8, 2017, by Summit (Oxford) Limited, a wholly owned subsidiary, from the U.S. Biomedical Advanced Research and Development Authority (BARDA).
Key Financial Metrics and Contract Value
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. The primary financial data relates to the new government contract:
- Base Period Funding: Approximately $32 million in federal government funding for a 12-month base period.
- Total Potential Funding: Up to approximately $62 million if all three option work segments are exercised.
- Option Funding: Up to an additional $30 million available through option segments.
- Payment Terms: Payments are expected monthly after the Company invoices BARDA for allowable incurred costs.
Material Changes and Contract Structure
The material change is the execution of a cost-sharing contract to fund the clinical and regulatory development of ridinilazole for the treatment of Clostridium difficile infections (CDI). Key structural elements include:
- Scope: The base period covers activities for two planned Phase 3 clinical trials, including site opening, manufacturing of clinical supply, and patient enrollment.
- Options: Three independent option work segments could extend the contract into 2022. These would support trial completion, final reporting, drug manufacturing for marketing approval, and the preparation and submission of marketing applications.
- Cost Sharing: The Company is responsible for a portion of costs for each segment, including any costs exceeding estimated amounts.
Outlook, Risks, and Intellectual Property
Management Commentary and Outlook: The contract supports the development of ridinilazole through potential marketing approval submission. The Company retains exclusive worldwide commercialization rights.
Risks and Contingencies:
- Termination: BARDA may terminate the agreement for convenience at any time or for uncured default.
- Government Rights: The U.S. government receives unlimited rights to use and disclose new data produced under the contract. It also holds a nonexclusive, royalty-free license to practice any "subject invention" conceived under the contract.
- March-in Rights: The government retains the right to require the Company to grant a license to a third party if the Company fails to achieve practical application of the invention or meet health/safety needs.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ due to clinical trial uncertainties, regulatory approvals, and funding availability.
Investor Verification Checklist
- Verify the specific cost-sharing percentages and the Company's estimated out-of-pocket obligations for the base and option periods.
- Confirm the timeline for the first option work segment, expected to start in 2018, and the milestones required for BARDA to exercise options.
- Review the full BARDA contract (to be filed as an exhibit to the Form 20-F) for detailed termination clauses and intellectual property definitions.
- Assess the Company's current cash runway to cover its portion of the costs and any potential overages before the first government payments are received.